Log in

NYSE:MYOVMyovant Sciences News Headlines

$12.74
-0.06 (-0.47 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.47
Now: $12.74
$12.87
50-Day Range
$7.84
MA: $11.40
$13.31
52-Week Range
$4.14
Now: $12.74
$19.58
Volume375,692 shs
Average Volume832,083 shs
Market Capitalization$1.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.6

Headlines

Myovant Sciences (NYSE MYOV) News Headlines

Source:
DateHeadline
Insider Buying: Myovant Sciences Ltd (NYSE:MYOV) Major Shareholder Purchases 37,897 Shares of StockInsider Buying: Myovant Sciences Ltd (NYSE:MYOV) Major Shareholder Purchases 37,897 Shares of Stock
www.marketbeat.com - May 21 at 2:27 PM
Myovant Sciences Ltd (NYSE:MYOV) Expected to Earn Q2 2021 Earnings of ($0.51) Per ShareMyovant Sciences Ltd (NYSE:MYOV) Expected to Earn Q2 2021 Earnings of ($0.51) Per Share
www.americanbankingnews.com - May 21 at 12:04 PM
Myovant Sciences Ltd (NYSE:MYOV) Major Shareholder Chemical Co. Ltd. Sumitomo Buys 84,812 SharesMyovant Sciences Ltd (NYSE:MYOV) Major Shareholder Chemical Co. Ltd. Sumitomo Buys 84,812 Shares
www.marketbeat.com - May 19 at 6:58 PM
Myovant Sciences Ltd (NYSE:MYOV) Receives Average Rating of "Buy" from AnalystsMyovant Sciences Ltd (NYSE:MYOV) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 19 at 5:31 PM
Myovant Sciences (NYSE:MYOV) PT Lowered to $27.00 at SVB LeerinkMyovant Sciences (NYSE:MYOV) PT Lowered to $27.00 at SVB Leerink
www.americanbankingnews.com - May 19 at 9:34 AM
Myovant Sciences (NYSE:MYOV) Announces  Earnings Results, Beats Expectations By $0.04 EPSMyovant Sciences (NYSE:MYOV) Announces Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - May 19 at 7:22 AM
Myovant Sciences EPS beats by $0.04Myovant Sciences EPS beats by $0.04
seekingalpha.com - May 18 at 7:12 PM
BRIEF-Myovant Sciences Q4 Loss Per Share $0.73BRIEF-Myovant Sciences Q4 Loss Per Share $0.73
www.reuters.com - May 18 at 7:12 PM
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2020Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2020
finance.yahoo.com - May 18 at 7:12 PM
Myovant Sciences Ltd (NYSE:MYOV) Major Shareholder Purchases $511,677.78 in StockMyovant Sciences Ltd (NYSE:MYOV) Major Shareholder Purchases $511,677.78 in Stock
www.marketbeat.com - May 15 at 3:39 PM
BRIEF-Myovant Sciences To Present New Data On Relugolix In Prostate Cancer At ASCOBRIEF-Myovant Sciences To Present New Data On Relugolix In Prostate Cancer At ASCO
www.reuters.com - May 14 at 10:46 PM
Myovant Sciences to Present New Data on Relugolix in Prostate Cancer at American Society of Clinical Oncology (ASCO) 2020 Annual MeetingMyovant Sciences to Present New Data on Relugolix in Prostate Cancer at American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
finance.yahoo.com - May 14 at 12:45 PM
Chemical Co. Ltd. Sumitomo Acquires 35,000 Shares of Myovant Sciences Ltd (NYSE:MYOV) StockChemical Co. Ltd. Sumitomo Acquires 35,000 Shares of Myovant Sciences Ltd (NYSE:MYOV) Stock
www.marketbeat.com - May 13 at 8:56 PM
Chemical Co. Ltd. Sumitomo Purchases 70,000 Shares of Myovant Sciences Ltd (NYSE:MYOV) StockChemical Co. Ltd. Sumitomo Purchases 70,000 Shares of Myovant Sciences Ltd (NYSE:MYOV) Stock
www.americanbankingnews.com - May 11 at 7:18 PM
Myovant Sciences Ltd (NYSE:MYOV) Expected to Post Earnings of -$0.78 Per ShareMyovant Sciences Ltd (NYSE:MYOV) Expected to Post Earnings of -$0.78 Per Share
www.americanbankingnews.com - May 11 at 2:22 AM
Reviewing Myovant Sciences (NYSE:MYOV) and Rexahn Pharmaceuticals (NYSE:REXN)Reviewing Myovant Sciences (NYSE:MYOV) and Rexahn Pharmaceuticals (NYSE:REXN)
www.americanbankingnews.com - May 10 at 4:28 AM
Were Smart Money Traders Right About Myovant Sciences Ltd. (MYOV)?Were Smart Money Traders Right About Myovant Sciences Ltd. (MYOV)?
finance.yahoo.com - May 7 at 4:44 PM
Myovant Sciences Ltd (NYSE:MYOV) Major Shareholder Chemical Co. Ltd. Sumitomo Purchases 100,000 SharesMyovant Sciences Ltd (NYSE:MYOV) Major Shareholder Chemical Co. Ltd. Sumitomo Purchases 100,000 Shares
www.americanbankingnews.com - May 5 at 8:42 PM
Myovant Sciences Ltd (NYSE:MYOV) Major Shareholder Purchases $604,000.00 in StockMyovant Sciences Ltd (NYSE:MYOV) Major Shareholder Purchases $604,000.00 in Stock
www.americanbankingnews.com - May 1 at 8:08 PM
Myovant Sciences Ltd (NYSE:MYOV) Short Interest UpdateMyovant Sciences Ltd (NYSE:MYOV) Short Interest Update
www.americanbankingnews.com - May 1 at 12:49 AM
Myovant Sciences Measures UpMyovant Sciences Measures Up
seekingalpha.com - April 29 at 11:46 PM
BRIEF-Sumitovant Biopharma Reports Publication Of Myovant AbstractsBRIEF-Sumitovant Biopharma Reports Publication Of Myovant Abstracts
www.reuters.com - April 29 at 6:46 PM
Myovant Sciences Announces Publication of Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies in Uterine Fibroids in Obstetrics & GynecologyMyovant Sciences Announces Publication of Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies in Uterine Fibroids in Obstetrics & Gynecology
finance.yahoo.com - April 27 at 11:49 AM
Myovant Squares Off with AbbVie On Endometriosis TreatmentMyovant Squares Off with AbbVie On Endometriosis Treatment
www.fool.com - April 26 at 12:34 PM
Relugolix Combination Therapy May Be The Way To Cope With Endometriosis SymptomsRelugolix Combination Therapy May Be The Way To Cope With Endometriosis Symptoms
www.forbes.com - April 26 at 7:30 AM
Sumitovant Biopharma Reports Key Clinical and Regulatory Milestones by Myovant SciencesSumitovant Biopharma Reports Key Clinical and Regulatory Milestones by Myovant Sciences
www.prnewswire.com - April 24 at 3:00 PM
BRIEF-Sumitovant Biopharma Reports Key Clinical And Regulatory Milestones By Myovant SciencesBRIEF-Sumitovant Biopharma Reports Key Clinical And Regulatory Milestones By Myovant Sciences
www.reuters.com - April 24 at 3:00 PM
IMMU Gets Early FDA Nod, KNSAs PN Trial Meets Goals, MYOV In Good SpiritsIMMU Gets Early FDA Nod, KNSA's PN Trial Meets Goals, MYOV In Good Spirits
www.nasdaq.com - April 23 at 3:31 AM
BRIEF-Myovant Sciences Announces Positive Results From Phase 3 Spirit 2 StudyBRIEF-Myovant Sciences Announces Positive Results From Phase 3 Spirit 2 Study
www.reuters.com - April 22 at 10:31 PM
Baird highlights biopharma with catalysts to come and 100% upsideBaird highlights biopharma with catalysts to come and 100% upside
seekingalpha.com - April 22 at 5:31 PM
Myovant up 7% premarket on successful relugolix studyMyovant up 7% premarket on successful relugolix study
seekingalpha.com - April 22 at 12:30 PM
Myovant Eyes Relugolix Approval for Advanced Prostate CancerMyovant Eyes Relugolix Approval for Advanced Prostate Cancer
www.nasdaq.com - April 22 at 12:30 PM
BRIEF-Myovant Sciences Submits New Drug Application To The FDA For RelugolixBRIEF-Myovant Sciences Submits New Drug Application To The FDA For Relugolix
www.reuters.com - April 21 at 9:29 PM
Against backdrop of shelter-in-place, Peninsula biotech asks FDA to approve prostate cancer drugAgainst backdrop of shelter-in-place, Peninsula biotech asks FDA to approve prostate cancer drug
finance.yahoo.com - April 21 at 9:29 PM
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Wednesday, April 22 to Discuss Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition StudyMyovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Wednesday, April 22 to Discuss Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study
finance.yahoo.com - April 21 at 4:28 PM
Myovant files U.S. application for relugolix for prostate cancerMyovant files U.S. application for relugolix for prostate cancer
seekingalpha.com - April 21 at 11:28 AM
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate CancerMyovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer
finance.yahoo.com - April 21 at 11:28 AM
Worldwide Endometriosis Treatment Drugs Market Forecast 2020-2024 Growth Drivers, Regional OutlookWorldwide Endometriosis Treatment Drugs Market Forecast 2020-2024 Growth Drivers, Regional Outlook
www.marketwatch.com - April 17 at 9:16 AM
Myovant Sciences (MYOV) Jumps: Stock Rises 8.3%Myovant Sciences (MYOV) Jumps: Stock Rises 8.3%
finance.yahoo.com - April 15 at 2:10 PM
Myovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual HealthMyovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual Health
finance.yahoo.com - April 14 at 1:07 PM
Why Myovant Sciences (MYOV) Stock Might be a Great PickWhy Myovant Sciences (MYOV) Stock Might be a Great Pick
finance.yahoo.com - April 9 at 12:23 PM
Why Myovant Sciences Is Trading Higher TodayWhy Myovant Sciences Is Trading Higher Today
www.benzinga.com - March 31 at 5:14 PM
Myovant Sciences and Gedeon Richter Enter into...Myovant Sciences and Gedeon Richter Enter into...
www.benzinga.com - March 31 at 3:24 AM
Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
finance.yahoo.com - March 31 at 3:24 AM
BRIEF-Myovant Sciences Cancels Presentation At The Barclays Global Healthcare Conference 2020BRIEF-Myovant Sciences Cancels Presentation At The Barclays Global Healthcare Conference 2020
www.reuters.com - March 11 at 12:13 AM
Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020
finance.yahoo.com - March 10 at 8:48 AM
Myovant Sciences files application in Europe for relugolix combo tabletMyovant Sciences files application in Europe for relugolix combo tablet
seekingalpha.com - March 9 at 12:42 PM
Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine FibroidsMyovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
finance.yahoo.com - March 9 at 12:42 PM
Myovant Sciences to Present at Upcoming March Investor ConferencesMyovant Sciences to Present at Upcoming March Investor Conferences
finance.yahoo.com - February 25 at 9:03 AM
Relative Strength Alert For Myovant SciencesRelative Strength Alert For Myovant Sciences
www.nasdaq.com - February 14 at 1:18 PM
This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.